|
|
Article: ISOTECHNIKA EXPANDS IMMUNOSUPPRESSIVE DRUG PIPELINE.
- Article from:
- Worldwide Biotech
- Article date:
- July 1, 2003
CopyrightCOPYRIGHT 2003 Worldwide Videotex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Isotechnika Inc. Edmonton, Alberta, has announced that the company is developing a novel immunosuppressive compound called TAFA93. This new therapeutic is a small molecule mTOR inhibitor; a class of drugs currently used in the prevention of organ rejection in transplantation and as a coated stent therapy in the treatment of coronary artery disease. The mechanism of action of TAFA93 is distinct from calcineurin inhibitors such as ISA247, Isotechnika's lead drug. Therefore, TAFA93 has the potential to be administered as a complimentary therapy with ISA247 in the prevention of organ rejection after transplantation.
In early preclinical studies, TAFA93 is ...